Plant Molecular Farming: Much More than Medicines.
Plant Molecular Farming: Much More than Medicines.
复制标题
DOI：
10.1146/annurev-anchem-071015-041706
复制
发表时间：
2016-06
影响因子：
8
通讯作者：
Marc Tschofen;D. Knopp;E. Hood;E. Stöger
中科院分区：
文献类型：
--
作者：
Marc Tschofen;D. Knopp;E. Hood;E. Stöger
植物已经成为与商业相关的药品和非药品生产系统。目前，市场上可获得的非药物产品数量超过了植物分子农业的医疗产品，反映出前者的开发时间更短，监管负担更低。非药物产品从植物生产系统的低成本和更大的可扩展性中获益更多，而不会产生与药物下游加工和纯化相关的高成本。在这篇综述中，我们探讨了植物性制造可以产生最大影响的领域，重点是用作研究级或诊断试剂、化妆品成分和生物传感器或生物催化剂的商业化产品，如抗体、酶和生长因子。展望了大批量、低利润的蛋白质，如工业酶，可作为粗提取物或未经加工的植物组织应用于饲料、生物燃料和造纸工业。
Plants have emerged as commercially relevant production systems for pharmaceutical and nonpharmaceutical products. Currently, the commercially available nonpharmaceutical products outnumber the medical products of plant molecular farming, reflecting the shorter development times and lower regulatory burden of the former. Nonpharmaceutical products benefit more from the low costs and greater scalability of plant production systems without incurring the high costs associated with downstream processing and purification of pharmaceuticals. In this review, we explore the areas where plant-based manufacturing can make the greatest impact, focusing on commercialized products such as antibodies, enzymes, and growth factors that are used as research-grade or diagnostic reagents, cosmetic ingredients, and biosensors or biocatalysts. An outlook is provided on high-volume, low-margin proteins such as industrial enzymes that can be applied as crude extracts or unprocessed plant tissues in the feed, biofuel, and papermaking industries.